JP2022009816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022009816A5 JP2022009816A5 JP2021178682A JP2021178682A JP2022009816A5 JP 2022009816 A5 JP2022009816 A5 JP 2022009816A5 JP 2021178682 A JP2021178682 A JP 2021178682A JP 2021178682 A JP2021178682 A JP 2021178682A JP 2022009816 A5 JP2022009816 A5 JP 2022009816A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- binding
- antigen
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 49
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 16
- 102000003859 Claudin-6 Human genes 0.000 claims 11
- 108090000229 Claudin-6 Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 4
- 241000024188 Andala Species 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000882908 Homo sapiens Claudin-3 Proteins 0.000 claims 1
- 101000882890 Homo sapiens Claudin-4 Proteins 0.000 claims 1
- 101000912661 Homo sapiens Claudin-9 Proteins 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050015 human CLDN3 Human genes 0.000 claims 1
- 102000050035 human CLDN4 Human genes 0.000 claims 1
- 102000044350 human CLDN9 Human genes 0.000 claims 1
- 102000050327 human TNFRSF9 Human genes 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020062881 | 2020-03-31 | ||
| JP2020062881 | 2020-03-31 | ||
| JP2020073335 | 2020-04-16 | ||
| JP2020073335 | 2020-04-16 | ||
| JP2021056457A JP6971419B2 (ja) | 2020-03-31 | 2021-03-30 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021056457A Division JP6971419B2 (ja) | 2020-03-31 | 2021-03-30 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022009816A JP2022009816A (ja) | 2022-01-14 |
| JP2022009816A5 true JP2022009816A5 (https=) | 2024-04-01 |
Family
ID=77928433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021056457A Active JP6971419B2 (ja) | 2020-03-31 | 2021-03-30 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
| JP2021178682A Pending JP2022009816A (ja) | 2020-03-31 | 2021-11-01 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021056457A Active JP6971419B2 (ja) | 2020-03-31 | 2021-03-30 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230220066A1 (https=) |
| EP (1) | EP4126956A4 (https=) |
| JP (2) | JP6971419B2 (https=) |
| KR (2) | KR102431028B1 (https=) |
| CN (1) | CN115397855A (https=) |
| AU (1) | AU2021247916A1 (https=) |
| BR (1) | BR112022017305A2 (https=) |
| CA (1) | CA3174094A1 (https=) |
| CL (2) | CL2022002625A1 (https=) |
| CO (1) | CO2022015202A2 (https=) |
| CR (2) | CR20250119A (https=) |
| IL (1) | IL296478A (https=) |
| MX (1) | MX2022012092A (https=) |
| PE (1) | PE20221760A1 (https=) |
| PH (1) | PH12022552323A1 (https=) |
| SG (1) | SG11202104264TA (https=) |
| TW (2) | TWI900776B (https=) |
| WO (1) | WO2021200939A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102813659B1 (ko) | 2013-11-11 | 2025-05-28 | 추가이 세이야쿠 가부시키가이샤 | 개변된 항체 가변영역을 포함하는 항원 결합 분자 |
| TWI831044B (zh) | 2014-11-11 | 2024-02-01 | 日商中外製藥股份有限公司 | 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法 |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| MX2022000111A (es) * | 2019-07-10 | 2022-02-10 | Chugai Pharmaceutical Co Ltd | Moleculas de union a claudina-6 y usos de las mismas. |
| EP4395823A4 (en) * | 2021-09-03 | 2025-07-16 | Novarock Biotherapeutics Ltd | BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2023053282A1 (ja) * | 2021-09-29 | 2023-04-06 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
| KR20240133746A (ko) * | 2022-01-09 | 2024-09-04 | 아이-맵 바이오파마 컴파니 리미티드 | 다중특이적 작제물 및 이의 용도 |
| JP7730432B2 (ja) * | 2022-10-19 | 2025-08-27 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| TW202430574A (zh) | 2022-11-30 | 2024-08-01 | 美商積分分子股份有限公司 | 針對密連蛋白６之抗體，包括其雙特異性格式 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2241578B1 (en) | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
| DK3305813T3 (da) | 2009-11-11 | 2020-04-20 | Astellas Pharma Inc | Antistoffer, der er specifikke for claudin 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| ES2989943T3 (es) | 2011-05-13 | 2024-11-28 | Astellas Pharma Inc | Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6 |
| JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| RU2016122041A (ru) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые анти-клаудин антитела и способы их применения |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP3568416A4 (en) * | 2017-01-13 | 2020-07-08 | Celdara Medical, LLC | TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS |
| TW201938194A (zh) * | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| US20210054076A1 (en) * | 2018-01-05 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US12509524B2 (en) * | 2018-09-28 | 2025-12-30 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
| MX2022000111A (es) * | 2019-07-10 | 2022-02-10 | Chugai Pharmaceutical Co Ltd | Moleculas de union a claudina-6 y usos de las mismas. |
-
2021
- 2021-03-30 CA CA3174094A patent/CA3174094A1/en active Pending
- 2021-03-30 US US17/913,899 patent/US20230220066A1/en active Pending
- 2021-03-30 CR CR20250119A patent/CR20250119A/es unknown
- 2021-03-30 WO PCT/JP2021/013526 patent/WO2021200939A1/en not_active Ceased
- 2021-03-30 KR KR1020217036902A patent/KR102431028B1/ko active Active
- 2021-03-30 BR BR112022017305A patent/BR112022017305A2/pt unknown
- 2021-03-30 EP EP21778912.2A patent/EP4126956A4/en not_active Withdrawn
- 2021-03-30 PE PE2022002151A patent/PE20221760A1/es unknown
- 2021-03-30 KR KR1020227027058A patent/KR20220149774A/ko not_active Ceased
- 2021-03-30 JP JP2021056457A patent/JP6971419B2/ja active Active
- 2021-03-30 TW TW111120832A patent/TWI900776B/zh active
- 2021-03-30 AU AU2021247916A patent/AU2021247916A1/en not_active Withdrawn
- 2021-03-30 PH PH1/2022/552323A patent/PH12022552323A1/en unknown
- 2021-03-30 IL IL296478A patent/IL296478A/en unknown
- 2021-03-30 CR CR20220540A patent/CR20220540A/es unknown
- 2021-03-30 TW TW110111555A patent/TWI770917B/zh active
- 2021-03-30 MX MX2022012092A patent/MX2022012092A/es unknown
- 2021-03-30 CN CN202180025880.6A patent/CN115397855A/zh active Pending
- 2021-03-30 SG SG11202104264TA patent/SG11202104264TA/en unknown
- 2021-11-01 JP JP2021178682A patent/JP2022009816A/ja active Pending
-
2022
- 2022-09-27 CL CL2022002625A patent/CL2022002625A1/es unknown
- 2022-10-26 CO CONC2022/0015202A patent/CO2022015202A2/es unknown
-
2023
- 2023-07-19 CL CL2023002099A patent/CL2023002099A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009816A5 (https=) | ||
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP7031810B2 (ja) | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 | |
| WO2020186974A1 (zh) | 一种双特异性抗体及其制备方法与应用 | |
| RS62151B1 (sr) | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu | |
| JP2018502050A5 (https=) | ||
| JP2021175391A5 (https=) | ||
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP2021513366A (ja) | 抗ｐｄ−１／抗ｈｅｒ２天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法 | |
| JP2024509910A5 (https=) | ||
| JP2025504909A5 (https=) | ||
| CN116964084A (zh) | 双特异性抗体 | |
| CN111378044A (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2024516098A5 (https=) | ||
| WO2022267936A1 (zh) | 特异性结合糖基化ceacam5的抗体 | |
| US20180371088A1 (en) | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY | |
| WO2023072217A1 (en) | Fusion proteins targeting cd3 and cd47 | |
| WO2024061224A1 (zh) | 抗her2抗体及其用途 | |
| CN111378045A (zh) | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 | |
| JP2024515301A5 (https=) | ||
| CN115433277A (zh) | 抗cd38兔重组单克隆抗体的制备及应用 | |
| CN116554340A (zh) | 新型长效化和高活性且更安全的抗体构建体 | |
| JP2025528101A (ja) | 多重特異性ポリペプチド複合体 |